Xiao X, Da G, Xie X, Liu X, Zhang L, Zhou B, Li H, Li P, Yang H, Chen H, Fei Y, Tsokos G C, Zhao L, Zhang X
Department of Rheumatology and Clinical Immunology, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.
State Key Laboratory of Difficult, Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
J Intern Med. 2021 Jul;290(1):101-115. doi: 10.1111/joim.13218. Epub 2020 Dec 19.
Infections are one of the most common causes of morbidity and mortality in patients with systemic lupus erythematosus (SLE). SLE patients have a higher risk of tuberculosis (TB) infection due to impaired immune defence.
To investigate the demographics, clinical characteristics and outcomes of patients with SLE and concomitant TB.
Medical records of SLE patients with TB who were admitted to Peking Union Medical College (PUMC) Hospital in 1983-2019 were retrospectively reviewed. Age- and sex-matched SLE inpatients without TB were randomly selected as controls. Clinical and laboratory features and treatment were analysed and compared, and subjects were followed up to assess their outcome.
Of the 10 469 SLE inpatients, 249 (2.4%) were diagnosed with TB. Compared with controls, SLE/TB + patients exhibited higher frequency of prior haematologic, mucocutaneous and musculoskeletal system involvement, and prior treatment with potent glucocorticoid/immunosuppressive agents (GC/ISA). Arthritis and alopecia, positive T-SPOT.TB test and lymphocytopenia were more common in SLE/TB + patients. SLE/TB + patients with lupus before TB (SLE → TB) had higher risk of miliary TB (22.8%) and intracranial TB (16.5%) than SLE/TB + patients with lupus after TB (TB → SLE). SLE/TB + patients exhibited shorter long-term survival than SLE/TB- patients; those with poorer in-hospital outcomes had more severe lymphocytopenia and had received less treatment with ISAs.
Systemic lupus erythematosus patients treated vigorously with GC/ISA should be alerted of increased risk of TB infection, especially miliary and intracranial TB. Positive T-SPOT.TB and lymphocytopenia served as discriminatory variables between SLE/TB + and SLE/TB- patients. Lymphocytopenia was associated with poorer outcomes in SLE/TB + patients.
感染是系统性红斑狼疮(SLE)患者发病和死亡的最常见原因之一。由于免疫防御功能受损,SLE患者发生结核(TB)感染的风险更高。
调查SLE合并TB患者的人口统计学特征、临床特点及预后。
回顾性分析1983年至2019年在北京协和医院住院的SLE合并TB患者的病历。随机选取年龄和性别匹配的无TB的SLE住院患者作为对照。分析比较临床和实验室特征及治疗情况,并对受试者进行随访以评估其预后。
在10469例SLE住院患者中,249例(2.4%)被诊断为TB。与对照组相比,SLE/TB+患者既往血液系统、皮肤黏膜及肌肉骨骼系统受累的频率更高,且既往接受过强效糖皮质激素/免疫抑制剂(GC/ISA)治疗。关节炎和脱发、T-SPOT.TB试验阳性及淋巴细胞减少在SLE/TB+患者中更为常见。TB前患狼疮的SLE/TB+患者(SLE→TB)发生粟粒性TB(22.8%)和颅内TB(16.5%)的风险高于TB后患狼疮的SLE/TB+患者(TB→SLE)。SLE/TB+患者的长期生存率低于SLE/TB-患者;住院结局较差的患者淋巴细胞减少更严重,且接受ISA治疗较少。
应警惕接受GC/ISA积极治疗的系统性红斑狼疮患者TB感染风险增加,尤其是粟粒性和颅内TB。T-SPOT.TB试验阳性和淋巴细胞减少是SLE/TB+与SLE/TB-患者之间的鉴别变量。淋巴细胞减少与SLE/TB+患者较差的预后相关。